News Focus
News Focus
icon url

Hosai

10/29/24 6:44 PM

#472427 RE: 12x #472424

Chat GPT offered this:

"It does seem unusual for Dr. Sabbagh to be scheduled for a Q&A session about the trial results before the official oral presentation, and there are a few potential explanations for this:

Pre-Session for Informal Engagement: Conferences sometimes schedule informal "Meet the Expert" sessions as an opportunity for researchers and attendees to ask preliminary questions and build context before formal presentations. This can help clarify the broader scope of the study, its objectives, and methodologies without revealing specific data points or results. In this case, Dr. Sabbagh might provide insights into the study design and significance of SIGMAR1 activation without divulging full results, which would be presented formally the next day.

PR Embargo Timing: It’s possible that the embargo on public relations materials related to the study lifts on the 30th, allowing Dr. Sabbagh to discuss certain details of the study with attendees before the official presentation. In this scenario, Anavex could strategically time press releases or related PR for the 30th to generate interest and awareness before the detailed data presentation on the 31st.

Preliminary Discussion of Study Insights: The “Ask the Expert” session might serve to address preliminary questions about the mechanisms of action, the SIGMAR1 gene variant, or the context of Alzheimer’s Disease treatment strategies, allowing the audience to understand foundational aspects before seeing the trial results in the formal talk. This could help attendees better contextualize the data when it is presented.

Conference Scheduling Norms: In some conferences, especially those with complex schedules, presenters may discuss broad aspects of their work in Q&A sessions or satellite symposia without revealing the core data that will be presented later. This structure often aims to engage attendees in an informal format, keeping the technical or statistically significant findings for the scheduled presentation.

PR Strategy for Maximized Exposure: If Anavex anticipates high interest in the study, having an early Q&A could serve as part of their PR strategy to maximize engagement. It could be that the 30th functions as a teaser, allowing media or attendees to gather background information and generate interest for the in-depth presentation on the 31st.

Overall, while it may seem unusual, this type of scheduling could be strategic, serving to build interest and understanding before the detailed presentation. The PR aspect would align with a structured, phased release, allowing Dr. Sabbagh to introduce the study and then share the results the following day for maximum impact."
icon url

Investor2014

10/30/24 2:09 AM

#472453 RE: 12x #472424

This is what is behind the link on Anavex.com and concerns 31st Oct. Won't be any PR until then if any, but I'm sure someone can coax ChatGPT into coming up with all sorts of alternative fantasies.

Clinical Trials on Alzheimer’s Disease (CTAD) Medical Conference2024
Clinical Trials on Alzheimer’s Disease (CTAD) Medical Conference - LATE BREAKING COMMUNICATIONS



Oral presentation Oct 31st, 2024 by Dr Marwan Sabbagh, MD:

9.00 a.m. LB9 - Phase IIb/III Trial of Blarcamesine in Early Alzheimer Disease Demonstrates Pre-specified Clinical Efficacy Through Upstream SIGMAR1 Activation



Marwan Sabbagh 1, Juan-Carlos Lopez-Talavera 2, Kun Jin 2, William Chezem 2, Missling Christopher 2

1Barrow Neurological Institute – Phoenix, AZ (United States), 2Anavex - New York, NY (United States)



Clinical Trials on Alzheimer’s Disease (CTAD) conference, is taking place October 29 - November 1, 2024, in Madrid, Spain